Clinical Trials

45 enrolled 14 charts

Hodgkin Disease

NCT01508312 2025-10-21

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

66 enrolled 14 charts

Hodgkin Disease

NCT01909934 2025-09-19

Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Phase 4 Completed

50 enrolled 22 charts

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT05442554 2025-09-18

A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Phase 4 Completed

10 enrolled 25 charts

Lymphoma, T-Cell

NCT03496779 2025-07-30

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

71 enrolled

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

26 enrolled

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT02616965 2025-04-04

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

16 enrolled

Lymphoma, T-Cell, Cutaneous

NCT04213209 2024-09-27

Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

Completed

95 enrolled 30 charts

Lymphoma, T-Cell, Peripheral

NCT02388490 2024-09-23

Bretuximab

25 enrolled 12 charts

Lymphoma, Recurrence

NCT02191930 2024-08-23

BVB

70 enrolled

Hodgkin Disease

NCT03217643 2024-06-20

EATL-001

14 enrolled

Enteropathy-Associated T-Cell Lymphoma

NCT01492088 2024-05-30

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

36 enrolled 26 charts

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT03013933 2024-02-22

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

29 enrolled

Hodgkin Disease

NCT02398240 2023-10-26

Brentuximab for Newly Diagnosed Hodgkin Disease

40 enrolled

Hodgkin Disease

NCT02572167 2022-11-08

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

93 enrolled 13 charts

Hodgkin Disease

NCT02292979 2022-08-19

BREACH

170 enrolled

Hodgkin Disease

NCT03302728 2022-05-19

EpiBrentlen

6 enrolled

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02429375 2022-05-12

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

7 enrolled 10 charts

Hodgkin Disease, Recurrence

NCT02086604 2022-02-17

Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

37 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01578967 2021-12-07

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Phase NA Completed

41 enrolled 14 charts

Hodgkin Disease

NCT02686346 2021-12-07

BV-ICE

53 enrolled

452 enrolled 16 charts 1 FDA

Hodgkin Disease, Recurrence

NCT01777152 2021-11-30

ECHELON-2

Phase 3 Completed

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT01780662 2021-10-28

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

46 enrolled 18 charts

Hodgkin Disease

NCT02298283 2021-07-26

BRAPP2

40 enrolled

Hodgkin Disease

NCT01100502 2021-05-14

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Phase 3 Completed

329 enrolled 15 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT01990534 2021-04-09

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Phase 4 Completed

60 enrolled 21 charts

Hematologic Diseases, Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02939014 2021-02-24

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

39 enrolled 26 charts

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

NCT01578499 2021-01-05

ALCANZA

Phase 3 Completed

131 enrolled 24 charts

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT02227433 2020-12-22

FIL_BVHD01

20 enrolled

Hodgkin Disease

NCT02505269 2020-08-24

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

34 enrolled 7 charts

Hodgkin Disease

NCT01657331 2020-07-17

SGN+Benda

71 enrolled

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

NCT02139592 2020-07-13

Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

Completed

292 enrolled 39 charts

Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT01830777 2020-04-14

Brentuximab Vedotin + Re-induction Chemotherapy for AML

Other hematologic neoplasm

22 enrolled

Leukemia, Myeloid, Acute

NCT02164006 2019-10-02

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

16 enrolled

Hodgkin Disease

NCT02822586 2019-08-30

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

5 enrolled

Mycosis Fungoides, Sezary Syndrome

NCT02243436 2019-04-24

Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

67 enrolled

Hodgkin Disease, Lymphoma

NCT01700751 2019-04-16

Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation

LymphoidMyeloidOther hematologic neoplasm

17 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01874054 2019-02-12

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

55 enrolled 14 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT01807598 2019-01-29

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

LymphoidMyeloidOther hematologic neoplasm

10 enrolled 14 charts

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT01569204 2018-10-29

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

100 enrolled

Hodgkin Disease

NCT02280785 2018-09-06

BRAN

33 enrolled

Lymphoma, Non-Hodgkin

NCT02567851 2018-05-11

BREVITY

38 enrolled

Hodgkin Disease, Lymphoma

NCT01393717 2018-04-26

Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma

57 enrolled 14 charts

Hodgkin Disease

NCT01534078 2018-02-20

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

34 enrolled 15 charts

Hodgkin Disease

NCT02244021 2018-02-09

BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV

13 enrolled